The robustness of radiographic progression-free survival (rPFS), as defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2), as a trial end point was evaluated in 1,717 patients with metastatic castration-resistant prostate cancer. The findings of the PREVAIL trial show that enzalutamide significantly reduced the risk of radiographic progression or death in all performed sensitivity analyses (P < 0.001). Overall survival and rPFS were positively correlated (Spearman ρ 0.89 and Kendall τ 0.72).
References
Rathkopf, D. E. et al. Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PREVAIL randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2017.5808 (2018)
Rights and permissions
About this article
Cite this article
Thoma, C. Validating radiographic progression-free survival. Nat Rev Urol 15, 263 (2018). https://doi.org/10.1038/nrurol.2018.46
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2018.46
